XENE Q3 2024 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$74M

Net Income

-$63M

EPS (Diluted)

$-0.81

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$836M

Total Liabilities

$38M

Stockholders' Equity

$798M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$74M	-$56M	-32.3%
Net Income	-$63M	-$48M	-29.6%